BioCryst Pharmaceuticals | BCRX - Los Gastos Financieros De La Deuda





Los Gastos Financieros De La Deuda Cambio Fecha
Alnylam Pharmaceuticals USD 69.29M 60.05M 2026-03
BioCryst Pharmaceuticals USD 14.14M 5.53M 2025-12
Chugai Pharma JPY 95M 260M 2025-12
Daiichi Sankyo JPY 2.16B 1.33B 2025-12
DBV Technologies USD 461K 323.71K 2025-03
Enanta Pharmaceuticals USD 1.96M 620K 2024-12
Gilead Sciences USD 240M 15M 2026-03
GlaxoSmithKline GBP 167M 21M 2026-03
Glaxosmithkline GBP 177.95M 6.05M 2025-09
Incyte USD 569K 13K 2026-03
Ionis Pharmaceuticals USD 17M 1000K 2026-03
Karyopharm Therapeutics USD 12.62M 1.24M 2025-12
Neurocrine Biosciences USD 1.1M 0 2024-03
Novavax USD 5.82M 342K 2025-12
PTC Therapeutics USD 2.87B 2.82B 2026-03
Regeneron Pharmaceuticals USD 12.9M 700K 2026-03
Roche Holding CHF 304M 7.5M 2025-06
Sarepta Therapeutics USD 20.84M 13.28M 2025-12
Ultragenyx Pharmaceutical USD 21M 2M 2026-03
Vertex Pharmaceuticals USD 3.3M 0 2025-12